Russian Pharmaceutical Technologies Overview
- Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$292K
- Investors
-
1
Russian Pharmaceutical Technologies General Information
Description
Developer of drugs and therapies in field of oncology. The company develops, researches and commercializes new drugs and technologies in the field of oncology and medicine.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Griboyedov canal nab. 130
- Liter A, Office 202
- Saint Petersburg, 190121
- Russia
+7 8 (000) 000-00-00
Russian Pharmaceutical Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Grant | 22-Jan-2014 | $292K | 000.00 | Completed | Startup | |
| 1. Angel (individual) | 22-Jan-2014 | 000.00 | 000.00 | Completed | Startup |
Russian Pharmaceutical Technologies Patents
Russian Pharmaceutical Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9957236-B2 | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases | Active | 22-May-2014 | 0000000000 | 00 |
| ES-2734649-T3 | Selective inhibitors that interfere with the interaction of the fibroblast growth factor receptor and frs2 for the prevention and treatment of cancer and other diseases | Active | 22-May-2014 | 0000000000 | |
| JP-2017530111-A | Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer | Granted | 22-May-2014 | 0000000000 | |
| US-20170183315-A1 | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases | Granted | 22-May-2014 | 0000000000 | 0 |
| JP-6365999-B2 | Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer | Active | 22-May-2014 | C07D239/42 |
Russian Pharmaceutical Technologies Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Tamara Timofeeva | Chief Executive Officer | ||
| Sergey Tulyandin | Chief Scientific Officer |
Russian Pharmaceutical Technologies Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Skolkovo Foundation | Limited Partner | 000 0000 | 000000 0 |